George Church

George Church is a pioneering geneticist and molecular engineer whose work has significantly advanced genomics and synthetic biology, leading to numerous biotech innovations. After co-developing the first direct genomic sequencing method in 1984 and playing an instrumental role in initiating the Human Genome Project, George Church went on to revolutionize genomics and synthetic biology through numerous innovations. During his Ph.D. studies in biochemistry and molecular biology at Harvard University, he contributed to understanding introns’ regulatory function in mitochondrial genomes and developed a method for direct genomic sequencing, bypassing bacterial cloning.

Joining Harvard Medical School as an assistant professor in 1986, Church continued his groundbreaking work, including the invention of molecular multiplexing and barcode tags in 1988, and co-inventing nanopore sequencing in 1995. In 2005, Church launched the Personal Genome Project, making human genomic and trait data publicly accessible and fostering a new era of personal genomics. His laboratory has been a hub for translational research, leading to the co-founding of over 50 biotech companies, including LS9, Inc. (2005), Knome (2007), Joule Unlimited (2007), Pathogenica (2009), Gen9 Bio (2009), Alacris (2010), and AbVitro (2010).

Recognized among the most influential people in biopharma by Fierce Pharma in 2022, Church currently holds roles as Robert Winthrop Professor of Genetics at Harvard Medical School and Professor of Health Sciences and Technology at Harvard and MIT. In 2025, he will join Lila Sciences as Chief Scientist, continuing to drive innovation at the intersection of genetics, engineering, and medicine.